Disease landscape
Prostate Cancer
Moderate limitations in the access to prostate cancer diagnosis and treatment were found in the Visegrád Group (V4) countries. The results for the combined GAP indicator vary across the analysed countries, with the scores differing by about 17 points. The variance in GAP scores is driven mainly by differences in the diagnostic quality and the limited access to the selected novel drugs.
Cross-Country
General GAP for Prostate Cancer
Compliance with guidelines
Of the 9 drugs recommended by the clinical practice guidelines, about 70% are available in the V4 group. The spread of results for this KPI is large (33 percentage points), indicating a wide variation in access to the latest authorized drugs in these countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected novel drugs
Drug access
Number of patients treated (2022)
Drug access
Population treated (%) - selected drugs*
*percentage of the population potentially eligible for treatment with selected drugs: Erleada, Nubeqa, Xtandi, Zytiga.
Main issues
- The average time to reimbursement for prostate cancer drugs in the V4 countries is almost 3.3 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.3 years.
- The proportion of patients in the target population treated with the selected novel drugs in V4 countries is relatively high - 50-80% of potentially eligible patients in V4 are treated with these options, with a substantial spread the indicator values of about 36%.
- All V4 states have a significant population burden in prostate cancer. The burden measured by DALYs (disability adjusted life-years) in these countries is however lower than the EU average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).